Skip to content
Apogee Biotechnology Corporation

Apogee Biotechnology Corporation

  • Welcome
  • News
  • Technology
  • Lead Compound
  • Contact Us / Policies

Enrollment Completed for Opaganib Phase 2/3 COVID-19 Study

Posted bylwm100 June 16, 2021 Leave a comment on Enrollment Completed for Opaganib Phase 2/3 COVID-19 Study

https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=4457&PID=0&IID=19347The

Posted bylwm100June 16, 2021Posted inUncategorized

Post navigation

Previous Post Previous post:
Positive Top Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib
Next Post Next post:
Analysis of Phase 2/3 Data Including a 62% Reduction in Mortality with Oral Opaganib in Moderately Severe COVID-19 Patients

Leave a comment

Cancel reply

Your email address will not be published. Required fields are marked *

Apogee Biotechnology Corporation, Proudly powered by WordPress.